USCOM LIMITED — Regulatory Filings 2013

May 7, 2013

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

New USCOM Method for Measurement of Heart Function

Wednesday 8th of May 2013: Uscom Limited (ASX code: UCM).

Uscom Limited today announced the publication of a new method for measurement of cardiovascular performance based on USCOM. The derivation and validation of the method was published in the British Journal of Anaesthesia by Professor Brendan Smith and Veronica Madigan. The publication represents 6 years of pure and clinical research between the authors.

The new parameter, the Smith Madigan Inotropy Index, is based on the unique measures of USCOM and provides a simple and improved method for identifying and treating all cardiovascular conditions including heart failure, hypertension and sepsis. Measurement of the Smith Madigan Inotropy Index can be performed in less than 2 minutes using the non-invasive USCOM, and replaces complex catheter based measurements that are invasive, time consuming, costly and are associated with the clinical risk of complications.

Professor Smith works for the NSW Department of Health as a consultant Anaesthetist and Intensivist and is a Professor with the School of Biomedical Sciences at the Charles Sturt University, Bathurst. His special interest is the management of sepsis and septic shock.

Professor Smith said, “USCOM has been a central part of my clinical practice for over eight years and the Inotropy Index has developed from this practice. The Inotropy Index is an improvement on other measures of cardiovascular function and will allow for greater application of the USCOM in clinical practice. Our team is currently working on incorporating these parameters into new clinical treatment algorithms to simplify and improve care of sepsis, heart failure, major surgery, circulatory disorders and hypertension. In our hospital the Inotropy Index is saving lives in these complex diseases and is a major component of the BUSH protocol for treatment of sepsis and septic shock.”

Executive Chairman of Uscom Limited, Rob Phillips said, “Professor Smith and Veronica Madigan are early adopters of USCOM and world leaders in the field of clinical haemodynamics. The Inotropy Index will change the way we look at cardiovascular function and is already saving lives and changing the management of sepsis and septic shock. Not only is the Inotropy Index a better measure of cardiovascular function, it can be acquired non-invasively in under 2 minutes.”

The Smith Madigan Inotropy Index is a key measure in the BUSH protocol for treatment of sepsis and septic shock. A study presented at the Society of Critical Care Medicine in January by Professor Smith demonstrated that adoption of the BUSH Protocol Australia wide between 20062012 would have saved 8,237 lives. The Smith Madigan Inotropy Index is an USCOM patent protected measure and will be released as a new feature on USCOM devices following this publication.

References:

Smith BE, Madigan VM, Non-invasive method for rapid bedside estimation of inotropy: Theory and preliminary clinical validation. British Journal of Anaesthesia 2013, DOI 10.1093/BJA/AET118. Smith BE, Phillips RA, Madigan V, West MJ. Decreased Mortality, Morbidity and Emergency Transport in Septic Shock; A New Protocol Based on Advanced Noninvasive Haemodynamics (USCOM) and Early Antibiotics. Crit Care Med 2012; 40(12):1023. doi: 10.1097/01.ccm.0000424114.76434.7a

Uscom Limited

ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an Australian medical device company which listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency and Intensive Care Medicine and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

USCOM has global regulatory approval and the device is currently marketed in North America, South America, Europe, the Middle East, Australia & New Zealand, China and SE Asia.

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Sarah Prince Company Secretary secretary@uscom.com.au